Pelthos Therapeutics Inc. (PTHS) Form 10-Q — May 14, 2026
Pelthos Therapeutics Inc. reported a net loss of $10,238,000 for the three months ended March 31, 2026. The company's revenue for the period was $10,906,000, primarily from net product sales of $10,665,000 for its lead product, ZELSUVMI, and $241,000 from license and collaboration revenues. The company's cash and cash equivalents increased to $31,976,000 as of March 31, 2026, from $17,973,000 as of December 31, 2025.
Key figures
- Eps Beat
- 0
- Revenue
- 10906
- Total Debt
- 110276
- Debt Amount
- 23283
- Revenue Yoy
- 0
- Total Assets
- 145378
- Cash Position
- 31976
- Deal Value Usd
- 0
- Interest Rate
- 16
- Maturity Date
- 2031-01-31
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 3475645
- Working Capital
- 44798
- Total Other Income
- 2850
- Royalty Rate On Sato
- 7
- Royalty Rate On Xepi
- 7
- Total Current Assets
- 69801
- Debt From Venture Loan
- 26356
- Royalty Rate On Zelsuvmi
- 13
- Total Operating Expenses
- 23994
- Revenue From Product Sales
- 10665
- Royalty Rate On Reedy Creek
- 25
- Total Current Liabilities
- 25003
- Debt From Convertible Notes
- 23283
- Milestone Payment For Zelsuvmi
- 5000
- Amortization Of Intangible Assets
- 1031
- Revenue From License And Collaboration
- 241
- Royalty Rate On Zelsuvmi After Initial Term
- 10.4
- Royalty Rate On Reedy Creek After Initial Term
- 10
Price after filing
1 day: 0.0%7 days: -2.1%30 days: +3.7%
Close on the filing date to close N calendar days later (from $27.69). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.